Clariane Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Clariane wird ein jährliches Gewinn- und Umsatzwachstum von 88.6% bzw. 5.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 88% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 1.7% betragen.

Wichtige Informationen

75.5%

Wachstumsrate der Gewinne

75.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	5.4%
Zukünftige Eigenkapitalrendite	2.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:KO2 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5,886	89	223	905	2
12/31/2025	5,578	81	180	826	2
12/31/2024	5,295	45	162	778	2
12/31/2023	4,996	-92	320	804	N/A
9/30/2023	4,865	-32	244	799	N/A
6/30/2023	4,735	28	168	794	N/A
3/31/2023	4,587	32	204	828	N/A
12/31/2022	4,438	36	239	862	N/A
6/30/2022	4,288	85	348	900	N/A
3/31/2022	4,212	92	330	870	N/A
12/31/2021	4,137	100	311	840	N/A
9/30/2021	4,047	76	279	818	N/A
6/30/2021	3,941	60	243	785	N/A
3/31/2021	3,857	50	259	790	N/A
12/31/2020	3,773	39	275	795	N/A
9/30/2020	3,728	57	310	765	N/A
6/30/2020	3,683	74	346	734	N/A
3/31/2020	3,648	94	393	750	N/A
12/31/2019	3,613	115	439	766	N/A
9/30/2019	3,542	117	352	687	N/A
6/30/2019	3,471	119	264	607	N/A
3/31/2019	3,404	121	188	492	N/A
12/31/2018	3,336	123	113	377	N/A
9/30/2018	3,280	152	139	371	N/A
6/30/2018	3,224	180	165	364	N/A
3/31/2018	3,177	172	181	375	N/A
12/31/2017	3,131	163	197	385	N/A
9/30/2017	3,091	150	N/A	353	N/A
6/30/2017	3,052	137	N/A	320	N/A
3/31/2017	3,017	134	N/A	314	N/A
12/31/2016	2,981	131	N/A	307	N/A
9/30/2016	2,880	87	N/A	296	N/A
6/30/2016	2,779	42	N/A	284	N/A
3/31/2016	2,676	50	N/A	264	N/A
12/31/2015	2,573	59	N/A	245	N/A
9/30/2015	2,553	77	N/A	271	N/A
6/30/2015	2,533	95	N/A	297	N/A
3/31/2015	2,378	78	N/A	272	N/A
12/31/2014	2,222	61	N/A	247	N/A
9/30/2014	1,938	44	N/A	186	N/A
6/30/2014	1,654	27	N/A	126	N/A
3/31/2014	1,505	28	N/A	122	N/A
12/31/2013	1,356	29	N/A	119	N/A
9/30/2013	1,286	29	N/A	118	N/A
6/30/2013	1,216	29	N/A	118	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KO2 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (0.7%).

Ertrag vs. Markt: KO2 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: KO2 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: KO2Die Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.3% pro Jahr).

Hohe Wachstumseinnahmen: KO2Die Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: KO2Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (1.7 %).

Clariane Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Korian Provides Sales Guidance for the Year 2022

Korian Provides Revenue Guidance for the Full Year 2021 and Full Year 2022

Recent updates

New minor risk - Shareholder dilution

Clariane SE has filed a Follow-on Equity Offering in the amount of €237.083186 million.

Clariane SE Appoints Sylvia Metayer as Non-Executive Director

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment improves as stock rises 22%

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 15%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 23%

Investor sentiment deteriorates as stock falls 36%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 21%

Full year 2022 earnings released

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Korian to Report First Half, 2023 Results on Jul 27, 2023

Investor sentiment deteriorated over the past week

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Investor sentiment deteriorated over the past week

High number of new directors

Korian Proposes Dividend

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Icade Santé SAS completed the acquisition of 2 nursing homes in Le Teilleul and Notre-Dame-de-Sanilhac from Korian (ENXTPA:KORI) for €13 million.

Korian Provides Sales Guidance for the Year 2022

First half 2021 earnings released: EPS €0.31 (vs €0.13 in 1H 2020)

Korian (ENXTPA : KORI) acquired a 90% stake in Santa Croce s.r.l.

Korian in Exclusive Talks to Acquire Osny Psychotherapy Centre in Val d’Oise

Icade Santé SAS acquired One Post-Acute Care Facility and Two Nursing Homes from Korian (ENXTPA:KORI).

Korian (ENXTPA:KORI) completed the acquisition of ITA Mental Health from Magnum Capital Industrial Partners.

Korian Approves Dividend, Payable on July 1, 2021

Upcoming dividend of €0.30 per share

Korian Provides Revenue Guidance for the Full Year 2021 and Full Year 2022

Korian (ENXTPA:KORI) signed an agreement to acquire ITA Mental Health from Magnum Capital Industrial Partners.

Full year 2020 earnings released

Revenue beats expectations

Korian (ENXTPA:KORI) acquired unknown minority stake in Viva Son Group.

New 90-day high: €32.34

Korian Demonstrates the Relevance of its Asset Smart Strategy through a Partnership with BNP Paribas Cardif and EDF Invest

Icade SA (ENXTPA:ICAD) agreed to acquire Four Nursing Homes in France from Korian (ENXTPA:KORI) for €33.5 million.

New 90-day high: €30.78

Korian (ENXTPA:KORI) completed the acquisition of Inicea Groupe from Antin Infrastructure Partners S.A.S.

Korian Signs Development Partnership with Aedifica in the Netherlands

Korian has completed a Follow-on Equity Offering in the amount of €400.250658 million.

Korian to Report First Half, 2021 Results on Jul 29, 2021

New 90-day low: €26.58

Korian to Report Fiscal Year 2020 Results on Feb 24, 2021

Korian (ENXTPA:KORI) reached a non binding deal to acquire Inicea Groupe for €360 million.

New 90-day low: €27.38

Korian Announces Executive Changes

Korian (ENXTPA:KORI) entered into an agreement to acquire Five Facilities near Amsterdam from Ontzorgd Wonen Groep B.V.

New 90-day low - €31.54

Korian (ENXTPA:KORI) acquired Santa Marinella.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken